Skip to main content
SpringerLink
Log in

Diabetes Typ 2

Gliflozin verbessert Urin-Metabolom auch bei nierengesunden Diabetikern

  • Journal club
  • Published:
Info Diabetologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur:

  1. Ferrannini E, Mark M, Mayoux E. CV-Protection in the EMPA-REG Outcome trial a "thrifty substrate" hypothesis. Diabetes Care 2016; 39(7):1108-4

  2. Mulder S, Heerspink HJL, Darshi M, et al. Effects of dapaglifozin on urine metabolites in people with type 2 diabetes. Diabetes Obes Metab 2019; 21 (11):2422-2428

  3. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 Inhibitor empaglifozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014;306(2): F194-F204

Download references

Author information

Authors and Affiliations

  1. FA f. Innere Medizin\/Kardiologie, Bahnhofstraße 2,, 97769, Bad Brückenau, Germany

    Emanuel Fritschka

Authors
  1. Emanuel Fritschka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emanuel Fritschka.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fritschka, E. Gliflozin verbessert Urin-Metabolom auch bei nierengesunden Diabetikern. Info Diabetol 15, 16–17 (2021). https://doi.org/10.1007/s15034-021-3701-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15034-021-3701-5

Search

Navigation